


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 7, 2006 (use as many sheets as necessary)		Complete if Known Application Number: 10/781,263 Filing Date: 2/19/2004 First Named Inventor: Yoshiyuki Inada Group Art Unit: 1626 Examiner Name: Deborah C. Lambkin Attorney Docket Number: 087147-0494	
Sheet	1	of	2



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
DL	B1	EP	0 461 039	B1	Hoechst Marion Roussel	12/11/1991		A
DL	B2	WO	95 21609	A	Ciba-Geigy AG	08/17/1995		
DL	B3	EP	0 533 058	B1	Hoechst AG	03/24/1993		A
DL	B4	AU	657478	B	Roussel-UCLAF	12/12/1991		
DL	B5	AU	659485	B	Hoechst AG	03/18/1993		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
DL	B6	BERKOW, The Merck Manual of Diagnosis and Therapy, 14 th Ed., 1982, Merck Sharp & Dome Research Laboratories, p. 2366.		
DL	B7	BORHANI et al., "The multicenter Isradipine/diuretic atherosclerosis study: A study of the antiatherogenic properties of isradipine in hypertensive patients," J. Cardiovasc. Pharm., vol. 18, no. Suppl. 3, 1991, pp. S15-S19, XP008037314.		
DL	B8	HAUSTEIN, "Heutiger Stand und Trends der Sklerodermie-Behandlung," Hautarzt, vol. 43, 1992, pp. 409-416, XP008037316.		
DL	B9	TOLLEFSON, "Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia," Biol. Psychiatry, vol. 27, 1990, pp. 1133-1142, XP008037307.		
DL	B10	DE ANGELIS, "Effect of calcium antagonists in the elevated plus-maze test of anxiety," European Journal of Pharmacology," vol. 183, no. 5, 1990, pp. 1974-1975, XP008037308.		
DL	B11	CHAMONTIN et al., "Effect d'un inhibiteur calcique, la nicardipine, sur la secretion de l'aldosterone au cours de l'hyperaldosteronisme primaire," Arch. Mal. Coeur, vol. 82, 1989, pp. 1237-1240, XP008037317.		

Examiner Signature	/Deborah Lambkin/	Date Considered	11/28/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form, with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/781,263
Date Submitted: September 7, 2006		Filing Date	2/19/2004
(use as many sheets as necessary)		First Named Inventor	Yoshiyuki Inada
		Group Art Unit	1626
		Examiner Name	Deborah C. Lambkin
		Attorney Docket Number	087147-0494
Sheet	2	of	2



NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DL	B12	BEATTY et al., "Elevation of intraocular pressure by calcium channel blockers," Arch. Ophthalmol., vol. 102, 1984, pp. 1072-1076, XP008037319.	
DL	B13	JOHNSON, "Calcium channel blockade and resistant bipolar depression," Irish J. Psychol. Med., vol. 8, 1991, pp. 50-51, XP008037311.	
DL	B14	WITZMANN, "Effect of spironolactone on intraocular pressure in glaucoma patients," Klinische Monatsblätter für Augenheilkunde, vol. 176, no. 3, 1980, pp. 445-446, XP008050793.	
DL	B15	REYNOLDS, Martindale The Extra Pharmacopoeia Thirtieth Edition, 1993, The Pharmaceutical Press, p. 806-832.	
DL	B16	PECZON et al., "Diuretic drugs in glaucoma," Am. J. Ophthalm., vol. 66, no. 4, 1968, pp. 680-683, XP002067602.	
DL	B17	FUMIHIKO OKADA, "Depression after treatment with thiazide diuretics for hypertension," Am. J. Psychiatry, vol. 142, no. 9, 1985, pp. 1101-1102, XP008037312.	
DL	B18	GRIFFING et al., "Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by Enalapril: a new angiotensin-converting enzyme inhibitor," Metabolism, vol. 32, no. 7, 1983, pp. 711-716, XP008037313.	
DL	B19	MATSUMOTO et al., "Effects of Aldosterone Receptor Antagonist and Angiotensin II Type I Receptor Blocker on Cardiac Transcriptional Factors and mRNA Expression in Rats With Myocardial Infarction," Circ. J., 2004, 68, pp. 376-382.	
DL	B20	INADA et al., "Antihypertensive Effects of a Highly Potent and long-Acting Angiotensin II Subtype-1 Receptor Antagonist...in Various Hypertensive Rats," J. Pharm. Exp. Ther., vol. 268, no. 3, March 1994, pp. 1540-1547, XP008014592.	

Examiner Signature	/Deborah Lambkin/	Date Considered	11/28/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.